Floatz logo

Vorbipiprant

Solid Tumor

Rottapharm BiotechSmall moleculePhase 1/2Active
CC
40/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
59/ 100

Competitive context

927 Active assets in the Solid Tumor cohort.

View all 50

Same molecule, other indications

Vorbipiprant is also rated in:

colorectal carcinomaDormant
CCC
Indicative ·
53 / 100
View asset →
Mismatch Repair Protein ProficientDormant
CCC
Indicative ·
48 / 100
View asset →
digestive system cancerDormant
CCC
Indicative ·
48 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →